Research Paper Volume 11, Issue 9 pp 2551—2564
MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway
Figure 1. Cisplatin resistance of CD133+ HCC cells. (A) CD133+ HCC cells were identified by using CD133 antibody in HepG2 and Huh7 cells. (B) Purity of sorted CD133+ and CD133- HepG2 and Huh7 cells was tested by flow cytometry. (C) CD133+ and CD133- HepG2 and Huh7 cells were treated with different concentrations of cisplatin (0~30 μM) for 48 h. Cell viability curve was conducted by MTT assays. (D) IC50 of cisplatin to CD133+ and CD133- HepG2 and Huh7 cells was calculated according to the MTT assays. *P<0.05.